A5065651999- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Rheumatoid Arthritis Research and Therapies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Pharmaceutical Economics and Policy
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Breast Cancer Treatment Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Statistical Methods in Clinical Trials
- Venous Thromboembolism Diagnosis and Management
- Spondyloarthritis Studies and Treatments
- Inflammatory Bowel Disease
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Meta-analysis and systematic reviews
- Chronic Myeloid Leukemia Treatments
Gilead Sciences (United States)
2020-2024
Amgen (United States)
2017-2021
University of Arizona
2014-2020
University of Arizona Cancer Center
2016
BackgroundThe antibody–drug conjugate sacituzumab govitecan (SG) prolongs progression-free survival and overall in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, we investigated its effect on health-related quality of life (HRQoL).MethodsThis analysis was based the open-label phase III ASCENT trial (NCT02574455). Adults mTNBC who had received ≥2 prior systemic therapies (≥1 setting) were randomised 1:1 to SG or treatment physician's choice (TPC;...
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality life (HRQoL) patient-reported outcome (PRO) findings from this study.
Nab-paclitaxel plus gemcitabine (NAB-P + GEM) and FOLFIRINOX have shown superior efficacy over (GEM) in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDA). Although incremental clinical benefits are modest, both treatments represent significant advances a high-mortality cancer. In this independent economic evaluation for US, aim was to estimate comparative cost-utility cost-effectiveness these three regimens from payer perspective.In absence direct comparison single trial,...
Abstract Background Understanding the evolving treatment patterns in patients with rheumatoid arthritis (RA) is important for rheumatologists to make best practice decisions and optimize treatment. Here, we describe among newly initiated on biologic and/or nonbiologic RA therapy over time after enrollment US Corrona registry. Methods This was a retrospective, cohort study of adult enrolled Patients were included this if they conventional synthetic disease-modifying antirheumatic drug...
Aims: To determine the cost-effectiveness of treatment sequences biologic disease-modifying anti-rheumatic drugs or Janus kinase/STAT pathway inhibitors (collectively referred to as bDMARDs) vs conventional DMARDs (cDMARDs) from US societal perspective for patients with moderately severely active rheumatoid arthritis (RA) inadequate responses cDMARDs.Materials and methods: An individual patient simulation model was developed that assesses impact treatments on disease based clinical trial...
The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses NAB-P+GEM from the payer perspective have not been conducted for UK.A Markov model simulating health outcomes and total costs was developed to estimate life years gained (LYG) quality-adjusted (QALY) incremental cost-effectiveness (ICER) cost-utility ratios (ICUR) patients with MPC a base case...
Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic nonbiologic medications with different mechanisms action. Data describing disease activity levels in RA not directly available claims databases but can be determined using a claims-based effectiveness algorithm. Rheumatology has benefited from recent introduction new drugs, many We provide an analysis this broader range medications.To (a) describe summarize TIMs...
Abstract This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic disease-modifying antirheumatic drug (csDMARD) TNFi/csDMARD combination therapy. retrospective analysis included adults with PsA who enrolled the Corrona PsA/spondyloarthritis between March 21, 2013 (registry initiation), and January 31, 2017, received an approved TNFi and/or csDMARD as “existing use”...
Etanercept (ETN) and adalimumab (ADA) are tumor necrosis factor inhibitors indicated for treatment of moderate to severe rheumatoid arthritis (RA) used as monotherapy or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) such methotrexate (MTX). Data on patterns costs ETN ADA monotherapies therapy MTX lacking biologic DMARD (bDMARD)-naive patients RA.
4113 Background: Per conference feedback we optimized our 2015 ASCO reported independent economic evaluation of GEM, NAB-P+GEM, and FFX in mPDA by improving survival curve fitting (exponential v. Weibull distributions) modifying disease monitoring. Methods: We used published direct efficacy estimates GEM or complemented NAB-P+GEM estimated with Bucher’s indirect comparison method. Kaplan Meier fit was tested for exponential parametric distributions. A state transition model full time horizon...
Abstract Background: For HR+/HER2- metastatic breast cancer (MBC) patients, after resistance to endocrine therapy (ET), treatment options are mostly limited traditional chemotherapies (CT) that offer poor survival and quality of life (QoL), creating an area unmet need. The antibody-drug conjugate sacituzumab govitecan (SG) comprises anti-Trop-2 antibody coupled SN-38 via a hydrolyzable linker. In the phase 3 TROPiCS-02 trial, heavily pretreated patients with relapsed/refractory MBC received...
e15704 Background: Classical pharmacoeconomic analysis methods may prove insufficient for the economic evaluation of novel cancer treatments, esp. in advanced/metastatic setting as it is important to calculate a reliable and credible estimation total cost outcomes. The application different parametric models impact estimates. Access individual patient data from randomized controlled (RCT) trials limited, hence digitization software used reproduce published Kaplan-Meier (K-M) curves estimate...
Background: Sub-analyses from the BEST trial in heart failure (HF) indicated that Arg389 homozygote patients may respond to bucindolol. Bucindolol is currently being evaluated genotype GENETIC-AF trial. Our aim conduct ex ante economic evaluations of genetic testing support β-blocker treatment HF.Methods: Using survival results two sub-analyses, we constructed a decision-tree model (time-horizon 18 months, divided into three 6-month cycles) estimate cost-effectiveness/utility with bucindolol...
Patients with moderate to severe rheumatoid arthritis (RA) occasionally increase their doses of tumor necrosis factor (TNF) inhibitors, especially the monoclonal antibody origin drugs such as adalimumab and infliximab, after inadequate response initial dose. Previous studies have evaluated cost-effectiveness various sequences treatment for RA in United States but not considered effect dose escalation.
Abstract Background The importance of adjusting for cross-study heterogeneity in control group response rates when conducting network meta-analyses (NMA) was demonstrated using a case study involving comparison biologics the treatment moderate-to-severe rheumatoid arthritis. Methods Bayesian NMAs were conducted American College Rheumatology (ACR) 50 based upon set randomized controlled trials (RCTs) identified by recently completed systematic review literature. In addition to performance an...
Abstract Background: In ASCENT, patients with mTNBC refractory to or relapsing after ≥2 prior chemotherapies (at least one in the metastatic setting) were randomized 1:1 receive sacituzumab govitecan (SG) single-agent treatment of physician’s choice (TPC) (capecitabine, eribulin, vinorelbine, gemcitabine). Primary endpoint was progression free survival. Secondary endpoints included overall survival, objective response rate, clinical benefit and safety. Here we examined whether health-related...